Search

Your search keyword '"Urba, Walter"' showing total 715 results

Search Constraints

Start Over You searched for: Author "Urba, Walter" Remove constraint Author: "Urba, Walter"
715 results on '"Urba, Walter"'

Search Results

1. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

2. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

3. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

4. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

5. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial

6. Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.

7. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

8. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

9. Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system

10. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

11. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

14. 680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma

15. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

16. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

17. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

18. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

19. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

20. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

21. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

22. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

23. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

24. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

25. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

26. Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma

34. SUPPLEMENTAL MATERIALS from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

39. Data from OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

40. supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

42. Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

44. Supplementary Methods from OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

45. Supplementary Figures 1 - 9 from OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

46. Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

48. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

50. A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Catalog

Books, media, physical & digital resources